Botulism in 4 Adults Following Cosmetic Injections With an Unlicensed, Highly Concentrated Botulinum Preparation | Infectious Diseases | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
 Micromedex Healthcare Series [database]. Greenwood Village, Colo: Micromedex Inc; 1974-2005
Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey.  Mov Disord. 1988;3:333-3353211180Google ScholarCrossref
Herrero BA, Ecklund AE, Streett CS.  et al.  Experimental botulism in monkeys—a clinical pathological study.  Exp Mol Pathol. 1967;6:84-954960839Google ScholarCrossref
Centers for Disease Control and Prevention.  Botulism in the United States, 1899-1996: Handbook for Epidemiologists, Clinicians, and Laboratory Workers. Atlanta, Ga: Centers for Disease Control and Prevention, National Center for Infectious Diseases; 1998
Comella CL, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiological findings.  Neurology. 1992;42:1307-13101620339Google ScholarCrossref
Bakheit AM, Ward CD, McLellan DL. Generalized botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases.  J Neurol Neurosurg Psychiatry. 1997;62:1989048725Google ScholarCrossref
Tacket CO, Shandera WX, Mann JM. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism.  Am J Med. 1984;76:794-7986720725Google ScholarCrossref
Chang GY, Ganguly G. Early antitoxin treatment in wound botulism results in better outcome.  Eur Neurol. 2003;49:151-15312646758Google ScholarCrossref
Sandrock CE, Murin S. Clinical predictors of respiratory failure and long-term outcome in black tar heroin-associated wound botulism.  Chest. 2001;120:562-56611502659Google ScholarCrossref
Centers for Disease Control and Prevention.  Select Agent Program. Accessed October 17, 2006
Brief Report
November 22/29, 2006

Botulism in 4 Adults Following Cosmetic Injections With an Unlicensed, Highly Concentrated Botulinum Preparation

Author Affiliations

Author Affiliations: Epidemic Intelligence Service (Drs Chertow and Tan), Division of Foodborne, Bacterial and Mycotic Diseases, National Center for Zoonotic, Vectorborne and Enteric Diseases (Drs Maslanka, Sobel, and Braden), Centers for Disease Control and Prevention, Atlanta, Ga; Division of Disease Control, Florida Department of Health, Tallahassee (Drs Chertow and Schulte); Division of Epidemiology, Environmental and Occupational Health, State of New Jersey Department of Health and Senior Services, Trenton (Drs Tan and Bresnitz); Miller School of Medicine, University of Miami, Miami, Fla (Drs Weisman and Bernstein); Florida Poison Information Center, Miami (Drs Weisman and Bernstein); University of Medicine and Dentistry of New Jersey, and the New Jersey Poison Information and Education System, Newark (Dr Marcus); Division of Epidemiology and Disease Control, Palm Beach County Health Department, Florida Department of Health, West Palm Beach (Dr Kumar); Director, Palm Beach County Health Department, Florida Department of Health, West Palm Beach (Dr Malecki).

JAMA. 2006;296(20):2476-2479. doi:10.1001/jama.296.20.2476

Context Botulism is a potentially lethal paralytic disease caused primarily by toxins of the anaerobic, spore-forming bacterium Clostridium botulinum. Although botulinum toxin A is available by prescription for cosmetic and therapeutic use, no cases of botulism with detectable serum toxin have previously been attributed to cosmetic or therapeutic botulinum toxin injections. On November 27, 2004, 4 suspected botulism case-patients with a link to cosmetic botulinum toxin injections were reported to the Centers for Disease Control and Prevention.

Objective To investigate the clinical, epidemiological, and laboratory aspects of 4 suspected cases of iatrogenic botulism.

Design, Setting, and Patients Case series on 4 botulism case-patients.

Main Outcome Measures Clinical characteristics of the 4 case-patients, epidemiological associations, and mouse bioassay neutralization test results from case-patient specimens and a toxin sample.

Results Clinical characteristics of the 4 case-patients were consistent with those of naturally occurring botulism. All case-patients had been injected with a highly concentrated, unlicensed preparation of botulinum toxin A and may have received doses 2857 times the estimated human lethal dose by injection. Pretreatment serum toxin levels in 3 of the 4 case-patients were equivalent to 21 to 43 times the estimated human lethal dose; pretreatment serum from the fourth epidemiologically linked case-patient was not available. A 100-μg vial of toxin taken from the same manufacturer's lot as toxin administered to the case-patients contained a toxin amount sufficient to kill approximately 14 286 adults by injection if disseminated evenly.

Conclusions These laboratory-confirmed cases of botulism demonstrate that clinical use of unlicensed botulinum toxin A can result in severe, life-threatening illness. Further education and regulation are needed to prevent the inappropriate marketing, sale, and clinical use of unlicensed botulinum toxin products.